scholarly journals The Effect of a Moderate Exercise Program on Serum Markers of Bone Metabolism in Dogs

Animals ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1481
Author(s):  
Zoran Vrbanac ◽  
Nika Brkljaca Bottegaro ◽  
Branimir Skrlin ◽  
Krunoslav Bojanic ◽  
Vesna Kusec ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Metabolism ◽  
Exercise Program ◽  
Bone Alkaline Phosphatase ◽  
Serum Markers ◽  
Treadmill Running ◽  
Moderate Intensity ◽  
Moderate Exercise

The beneficial effect of physical activity on the musculoskeletal health in dogs is well recognized, but the level of intensity, duration, and frequency of exercise is not fully described. Measurement of serum markers of bone metabolism (bone alkaline phosphatase and osteocalcin as bone formation markers and C-terminal telopeptide as bone resorption marker) during four months of organized moderate-intensity physical training in Labrador retriever and Golden retriever dogs aged between 11.7–24.4 months, showed variations of bone metabolism. Dogs were included in treadmill running sessions for 25 min, three times per week. Blood samples were taken at the beginning of the program (baseline), after two months (mid-term) and at the end of the study after four months. The values of bone alkaline phosphatase and osteocalcin significantly decreased following two months of exercise program. Bone alkaline phosphatase increased by the end of four-month training cycle, but did not reach baseline value. Osteocalcin levels continued to decrease towards the end of the study. C-terminal telopeptide concentrations did not significantly change throughout the study duration. The results of this study show that aerobic exercise of moderate-intensity caused an initial decrease in bone formation followed by an increase of bone alkaline phosphatase and a further decrease of osteocalcin concentration. The response of two formation markers can be explained by the different stage of osteoblast activity that they express. In summary, moderate exercise resulted in no change in bone resorption, and a mild bone formation in young developing dogs.

Changes in bone metabolism associated with exposure to industrial vibration

2020 ◽  
pp. 766-766
Author(s):  
A. V. Sukhova ◽  
E. N. Kryuchkova
Keyword(s):  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Metabolism ◽  
Biochemical Markers ◽  
Mineral Density ◽  
Local Vibration ◽  
Markers Of Bone Formation

The influence of general and local vibration on bone remodeling processes is investigated. The interrelations between the long - term exposure of industrial vibration and indicators of bone mineral density (T-and Z-criteria), biochemical markers of bone formation (osteocalcin, alkaline phosphatase) and bone resorption (ionized calcium, calcium/creatinine) were established.

Changes in Bone Metabolism Induced by Short-Term Treatment with G-CSF for the Mobilization of Allogeneic Hematopoietic Progenitor Cells.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1772-1772
Author(s):  
Frank P. Kroschinsky ◽  
Sybille Bergmann ◽  
Kirsten Poppe-Thiede ◽  
Gabriele Siegert ◽  
Claudia Rutt ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Stem Cell ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Metabolism ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Normal Ranges

Abstract Short-term treatment with granulocyte colony-stimulating factor (G-CSF) has become a standard procedure for the mobilization of allogeneic peripheral blood progenitor cells (PBPC) in healthy donors. While osteopenia was observed after G-CSF long-term treatment in patients with chronic neutropenia and in G-CSF overexpressing animal models, the information about the effects of G-SCF priming in PBPC donors is limited. Bone pain as the most frequent acute toxicity and the transient increase of serum alkaline phosphatase suggest an effect on bone metabolism also during G-CSF treatment for mobilization. A total of 93 unrelated stem cell donors (21 female, 72 male; median age 35 years) were included in a prospective study to investigate the changes in bone metabolism induced by short-term treatment with G-CSF. Mobilization treatment consisted of 7.5 μg/kg body weight lenograstim (Granocyte™, Chugai Pharma Inc., Tokyo, Japan) for five days. Leukaphereses were performed on day 5 and 6. Samples of blood and urine were taken at pre-donation health-check (before rhG-CSF stimulation, baseline), at the first day of apheresis (leukapheresis) and four weeks after donation (follow-up) and tested for a panel of biochemical markers for bone formation and bone resorption. Stem cell collections were not performed in all donors who were included at baseline, therefore data from leukapheresis are available from 73 donors, and 63 donors were examined at follow-up. Serum bone alkaline phosphatase (BAP) and serum ostase which are both markers for bone formation significantly increased from baseline to leukapheresis (p<0.0001). Both returned to baseline values within 4 weeks after donation. In contrast tartrat-resistent alkaline phosphatase (TRAP) 5b, which is produced by osteoclasts, was found to be decreased at leukapheresis (p=0.001) and at follow-up (p=0.005). The collagen type I crosslinks in urine increased significantly from baseline to follow-up (telopeptides p=0.022; deoxypyridinoline p=0,012). The ligand of receptor activator of NF-kB (RANKL) and osteoprotergerin (OPG), which are members of the TNF receptor family and play a role in the regulation of osteoclast recruitment were also affected by G-CSF treatment, which was reflected by a significant increase of OPG/RANKL-ratio (p=0.01). Serum parathormon (PTH) showed a highly significant increase from baseline to leukapheresis (p<0.0001), but was found at normal ranges in all donors at follow-up. Pearson’s correlation of bone markers with circulating CD34+ hematopoietic progenitors before first leukapheresis did not reveal an impact of these parameters on mobilization efficacy. In conclusion the results confirm the influence of G-CSF short-term treatment on bone metabolism in allogeneic stem cell donors. An initial osteoblastic stimulation is followed by a period of increased bone resorption which seems to be not finished 4 weeks after G-CSF treatment. However, the changes in urine crosslink concentrations occurred within the normal ranges of the used assays in the vast majority of donors and therefore we do not assume an impact on the safety of the mobilization procedure. The complex regulation of bone metabolism by humoral and cellular effectors and the cause of transient hyperparathyroidism need further investigations.

The changes in bone turnover markers of female systemic lupus erythematousus patients without glucocorticoid

Lupus ◽  
2021 ◽  
Vol 30 (6) ◽  
pp. 965-971
Author(s):  
Wang Tianle ◽  
Zhang Yingying ◽  
Hong Baojian ◽  
Gu Juanfang ◽  
Wang Hongzhi ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Bone Metabolism ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Amino Terminal ◽  
Normal People ◽  
Turnover Markers

Objectives SLE is a chronic autoimmune disease, which can affect the level of bone metabolism and increase the risk of osteoporosis and fracture. The purpose of this research is to study the effect of SLE on bone turnover markers without the influence of glucocorticoids. Methods A total of 865 female subjects were recruited from Zhejiang Provincial People’s Hospital and the First Hospital of Jiaxing, including 391 SLE patients without the influence of glucocorticoids and 474 non-SLE people. We detected Bone turnover markers including amino-terminal propeptide of type 1 procollagen (P1NP), C-terminal turnover of β - I collagen (β-CTX), N-terminal midfragment of osteocalcin (NMID) and 25(OH)D, and analyzed the difference in Bone turnover markers between the SLE group and the control group, as well as the influence of age and season on bone metabolism in female SLE patients. Results In the SLE group, the average age was 43.93±13.95 years old. In the control group, the average age was 44.84±11.42 years old. There was no difference between the two groups (t = 1.03, P = 0.30). P1NP, NMID and 25(OH)D in the SLE group were significantly lower than those in the control group (Z = 8.44, p < 0.001; Z = 14.41, p < 0.001; Z = 2.19, p = 0.029), and β-CTX in the SLE group was significantly higher than that in the control group (Z = 2.61, p = 0.009). In addition, the levers of β-CTX, NMID, P1NP and 25(OH)D in older SLE female patients were statistically significantly higher than those in younger (ρ = 0.104, p = 0.041; ρ = 0.223, p < 0.001; ρ = 0.105, p = 0.038; ρ = 0.289, p < 0.001). Moreover, β-CTX reached a high value in summer and PINP reached a low value in winter. Conclusion The bone formation markers of female SLE patients without glucocorticoid were lower than those of normal people and the bone resorption marker was higher than that of normal people. The 25 (OH) D of female SLE patients without glucocorticoid was lower than that of normal people. The risk of osteoporosis and fracture may be higher in elderly women with SLE. The bone resorption level of female SLE patients is high in summer and the bone formation level is low in winter.

scholarly journals SLPI is a critical mediator that controls PTH-induced bone formation

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Akito Morimoto ◽  
Junichi Kikuta ◽  
Keizo Nishikawa ◽  
Takao Sudo ◽  
Maki Uenaka ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Bone Resorption ◽  
Bone Formation ◽  
Protease Inhibitor ◽  
Bone Metabolism ◽  
Serine Protease ◽  
Serine Protease Inhibitor ◽  
Secretory Leukocyte Protease Inhibitor ◽  
Bone Imaging ◽  
Genetic Ablation

AbstractOsteoclastic bone resorption and osteoblastic bone formation/replenishment are closely coupled in bone metabolism. Anabolic parathyroid hormone (PTH), which is commonly used for treating osteoporosis, shifts the balance from osteoclastic to osteoblastic, although it is unclear how these cells are coordinately regulated by PTH. Here, we identify a serine protease inhibitor, secretory leukocyte protease inhibitor (SLPI), as a critical mediator that is involved in the PTH-mediated shift to the osteoblastic phase. Slpi is highly upregulated in osteoblasts by PTH, while genetic ablation of Slpi severely impairs PTH-induced bone formation. Slpi induction in osteoblasts enhances its differentiation, and increases osteoblast–osteoclast contact, thereby suppressing osteoclastic function. Intravital bone imaging reveals that the PTH-mediated association between osteoblasts and osteoclasts is disrupted in the absence of SLPI. Collectively, these results demonstrate that SLPI regulates the communication between osteoblasts and osteoclasts to promote PTH-induced bone anabolism.

scholarly journals Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis

2021 ◽  
Vol 8 ◽  
Author(s):  
Julia Mentzel ◽  
Tabea Kynast ◽  
Johannes Kohlmann ◽  
Holger Kirsten ◽  
Matthias Blüher ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Metabolism ◽  
Type I Collagen ◽  
Skin Inflammation ◽  
Serum Levels ◽  
Serum Markers ◽  
Chronic Inflammatory Disease ◽  
Type I ◽  
Patient Counseling ◽  
Type I Procollagen

Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring.

Biomarkers of bone metabolism in horses: Ante-mortem versus post-mortem correlation in serum and aqueous humour

2002 ◽  
Vol 15 (02) ◽  
pp. 67-71
Author(s):  
L. T. Glickman ◽  
N. W. Glickman ◽  
E. S. Rasmussen ◽  
S. J. Carlson ◽  
G. J. Breur ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Metabolism ◽  
Aqueous Humour ◽  
Bone Alkaline Phosphatase ◽  
Serum Marker ◽  
Post Mortem ◽  
Potential Marker ◽  
Serum Ictp

SummaryThe objective of this study was to determine the correlation between ante-mortem and 24-hour postmortem concentrations of four markers of bone metabolism in equine serum and aqueous humour. The markers evaluated were osteocalcin, bone alkaline phosphatase, carboxyterminal propeptide of type-1 procollagen and carboxyterminal cross-linked telopeptide of type-1 collagen (ICTP). The concentrations of these markers were poorly correlated (P > 0.05) between aqueous humour and serum. ICTP was the only serum marker significantly correlated (r = 0.93) between ante- and post-mortem samples. ICTP is, therefore, a potential marker for evaluating antemortem markers of bone metabolism in dead horses.

Morphometry and calcium contents in appendicular and axial bones of exercised ovariectomized rats

1985 ◽  
Vol 248 (1) ◽  
pp. R12-R17 ◽  
Author(s):  
R. L. Pohlman ◽  
L. A. Darby ◽  
A. J. Lechner
Keyword(s):  
Tensile Strength ◽  
Calcium Concentration ◽  
Exercise Program ◽  
Average Stress ◽  
Treadmill Running ◽  
Ovariectomized Rats ◽  
Moderate Exercise ◽  
Sprague Dawley ◽  
Length Of Treatment ◽  
Calcium Status

To determine the effects of exercise and ovariectomy on calcium status in selected appendicular and axial bones, female Sprague-Dawley (8-9 mo) rats were assigned to groups based on the following combinations: control (C) or ovariectomized (O); sedentary (S) or exercised (E); and length of treatment (2 or 4 mo). Exercise consisted of treadmill running for 1 h/day, 5 days/wk at a speed of 14.1 m/min and 8 degrees elevation. After death, femurs, tibia-fibula complexes, ribs (T7), and vertebrae (T7) were excised, cleaned, and weighed, and selected morphometrics were measured. Tensile strength was measured for the femurs, and all bones were then acid-hydrolyzed and calcium concentration determined spectrophotometrically. Bone [Ca2+] was significantly greater for CE and OE animals when compared with their sedentary counterparts (CS, OS). Within 4 mo calcium losses were evident in the femur and tibia of the ovariectomized animals, and the moderate exercise program was of insufficient intensity to alter this loss. The average stress to failure for femur from all groups was 1.13 +/- 0.11 N/m2. However, the effects of exercise appeared beneficial in the axial bones where [Ca2+] increased in the ovariectomized animals.

scholarly journals Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta

2007 ◽  
Vol 53 (6) ◽  
pp. 1109-1114 ◽  
Author(s):  
Tim Cundy ◽  
Anne Horne ◽  
Mark Bolland ◽  
Greg Gamble ◽  
James Davidson
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Formation ◽  
Bone Mass ◽  
Osteogenesis Imperfecta ◽  
Plasma Concentrations ◽  
Bone Alkaline Phosphatase ◽  
Type I ◽  
Low Bone Mass ◽  
Bone Formation Markers ◽  
Discriminant Ability

Abstract Background: Plasma concentrations of procollagen peptides are decreased in osteogenesis imperfecta (OI), whereas other bone formation markers may be increased. We examined the utility of combining these markers in the diagnosis of OI in adults. Methods: We measured plasma concentrations of procollagen-1 N-peptide (P1NP), osteocalcin, and bone alkaline phosphatase in 24 patients with nondeforming OI, 25 patients with low bone mass due to other causes, and 38 age- and sex-matched controls. The discriminant ability of various test combinations was assessed by the construction of ROC curves. Results: The median (range) ratio of osteocalcin to P1NP was significantly greater in patients with type I OI [1.75 (0.80–3.86)] than in controls [0.59 (0.34–0.90)] and patients with other causes of low bone mass [0.48 (0.05–1.38); P &lt;0.0001]. This ratio allowed nearly complete differentiation between healthy controls and patients with type I OI, but not patients with type IV OI. With a cutoff of 0.97 for osteocalcin:P1NP, the sensitivity and specificity were maximized at 95% (95% CI 76%–100%) and 88% (69%–97%), respectively, for patients with other causes of low bone mass vs those with type I OI only. For patients with other causes of low bone mass vs all OI patients, sensitivity and specificity were 83% (63%–95%) and 88% (69%–97%), respectively. The addition of bone alkaline phosphatase data did not improve the discriminant ability of the osteocalcin:P1NP ratio. Conclusions: The osteocalcin:P1NP ratio is a sensitive and specific test for type I OI in adults, but it has less utility in the diagnosis of other types of nondeforming OI.

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4668-4668
Author(s):  
Ellin Berman ◽  
Maria Nicolaides ◽  
Nicolas Sauter ◽  
Suzanne Chanel ◽  
Brianne Wilson ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Bone Formation ◽  
Mineral Metabolism ◽  
Fractional Excretion ◽  
Bone Alkaline Phosphatase ◽  
Hypophosphatemic Rickets ◽  
Common Side Effect ◽  
Time Interval ◽  
Low Levels

Abstract Imatinib is a tyrosine kinase that effectively inhibits the bcr-abl fusion protein in Philadelphia (Ph) chromosome positive CML and c-kit, which is overexpressed in gastrointestinal stomal tumors (GIST). We identified a group of patients treated with Imatinib at Memorial Hospital who developed low phosphate (PO4) levels and studied metabolic bone and mineral parameters associated with this finding. A total of 61 patients who received a prescription for Imatinib from the hospital pharmacy were screened to determine whether a PO4 level had ever been drawn. Of these, 26 had at least one PO4 level, and 10 of these (38%) had a low value (&lt;2.5 mg/dL).Patients samples were then studied for calcium (Ca++), parathyroid horme (PTH), 25-(OH)-vitamin D and 1,25-(OH)2-vitamin D, as well as serum markers of bone formation (bone alkaline phosphatase and osteocalcin) and resorption (N-telopeptide). Urinary calcium and PO4 were measured and fractional excretion of PO4 (FEPO4) was calculated as well. A total of 10 patients (8 men, 2 women) median age 47 (range 32–60) with CML (n=8) or GIST (n=2) were studied. The median time interval between diagnosis and starting Imatinib was 3.8 mos (range 0.4–161) and the median interval between starting Imatinib and first low PO4 was 3.9 mos (range 0.3–23). Results of Bone Metabolism UPIN PO4 Calcium PTH FePO4 N-Telopep Osteocalcin Bone Alk phos ND: Not done: NMA: No measurable amount; 25-(OH)-vitD levels were low to mid-normal, and 1,25-(OH)2 vit D levels were typically borderline high or elevated (data not shown) 2.5–4.2mg/dL 8.5–10.5mg/dL 10–65pg/mL &lt; 5% 5.5–19.5nM 3.1–12.7ng/ml 15–441U/L 1 2.0 8.7 84 25 ND ND ND 2 1.7 8.6 97 24 ND ND ND 3 2.3 9.4 68 44 ND ND ND 4 1.9 9.5 84 25 7.1 3.7 18 5 1.8 8.9 85 17 6.2 NMA 15 6 2.1 9.3 83 23 ND ND ND 7 1.7 8.7 57 16 5.6 NMA 17 8 1.3 8.1 136 38 10.1 NMA 53 9 2.3 9.2 81 10 13.4 NMA 17 10 2.1 8.9 41 17 5.8 2.6 15 Two patients who temporarily stopped Imatinib had normalization of their PO4, which again decreased upon resumption of the drug. In summary, patients who develop hypophosphatemia while on Imatinib have low-normal to mildly low serum Ca++ but elevated PTH, elevated FEPO4, low-normal levels of N-telopeptide, very low levels of osteocalcin, and low levels of bone alkaline phosphatase. These values distinctly differ from patients with either inherited or tumor induced forms of hypophosphatemia with renal phosphate wasting (X-linked hypophosphatemic rickets, adult dominant hypophosphatemic rickets, and tumor-induced osteomalacia). Our preliminary data suggest that in some patients, Imatinib results in profound suppression of bone formation and mild suppression of bone resorption, leading to a state of hypodynamic bone remodeling. Further investigation is planned comparing patients on Imatinib who become hypophosphatemic and those who do not. Better characterization of bone and mineral metabolism in this setting is important for several reasons: (1) myalgias from Imatinb, a common side effect, may be related to hyphophosphatemia and correctible with appropriate replacement; (2) while these data are premature, it is conceivable that Imatinib might be useful in situations where suppression of bone formation and turnover is desirable, such as in osteoblastic bone metastases, osteopetrosis, and other diseases of abnormally increased bone formation.

Sign in / Sign up

Export Citation Format

Share Document